As of November 6, 2026, Propanc Biopharma, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on July 14, 2026, naming 1 appointment. The latest filing names Carlo Campiciano, appointed (Form 8-K, July 14, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Propanc Biopharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Propanc Biopharma, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-07-14. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Propanc Biopharma, Inc. files it.
Also on the record for Propanc Biopharma, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 14, 2025 | Stake report, Schedule 13G/A, by Ionic Ventures, LLC | — | 5%+ stakes | Source |
| August 19, 2025 | Stake report, Schedule 13G, by Ionic Ventures, LLC | 9.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Propanc Biopharma, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Propanc Biopharma, Inc. and the records around it.
Propanc Biopharma, Inc. elsewhere on the record
Companies that share a holder
- Ionic Ventures, LLC also filed stake reports on 3 other companies: Algorhythm Holdings, Inc. (May 2026), Jet.AI Inc. (May 2026)
Watch Propanc Biopharma, Inc.
Get an email when Propanc Biopharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Propanc Biopharma, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Propanc Biopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Propanc Biopharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-14 | In | 8-K, 2026-07-14 |
New leaders reset buying decisions — get the Full Report on Propanc Biopharma, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Propanc Biopharma, Inc., with the record behind each one.
Find candidates like senior executive at Propanc Biopharma, Inc.Every change, in the filing's words
Appointed: Carlo Campiciano
That same day, the Board filled the vacancy on the Board left by Ms. Van Broekhoven's resignation and appointed Carlo Campiciano to serve on the Board until his resignation or removal.
- Effective July 8, 2026, Annie Van Broekhoven retired and stepped down from the Board of Directors (the "Board") of Propanc Biopharma, Inc. (the "Company") and the Company accepted her resignation.
- Mr. Campiciano is a qualified accountant and member of the Institute of Public Accountants in Australia, and has extensive business experience in taxation, finance operations, planning and financial strategy.
- Mr. Campiciano obtained a Master of Entrepreneurship and Innovation from Swinburne University of Technology, Graduate Diploma in Computing from Monash University Caulfield (formerly Caulfield Institute of Technology) as well as a Bachelor of Business (Accounting) from RMIT University and Certificate in Corporate Governance from the Governance Institute.
- Mr. Campiciano has been the CFO and Company Secretary of MedAdvisor Limited, a company listed on the Australian Securities Exchange (ASX).
- Mr. Campiciano was part of the foundation team that launched MedAdvisor in 2012 and since its launch has been key in raising several rounds of capital, as well as the company's listing on the ASX in December 2015.
Tools for this story
Each opens in a new tab, filled in for Propanc Biopharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.